Ion Channels in Obesity: Pathophysiology and Potential Therapeutic Targets

Luiz H. C. Vasconcelos1, Iara L. L. Souza1, Lilian S. Pinheiro1 and Bagnólia A. Silva1,2*

1 Laboratório de Farmacologia Funcional Prof. George Thomas, Programa de Pós-graduação em Produtos Naturais e Sintéticos Bioativos, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Brazil, 2 Departamento de Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Brazil

Obesity is a multifactorial disease related to metabolic disorders and associated with genetic determinants. Currently, ion channels activity has been linked to many of these disorders, in addition to the central regulation of food intake, energetic balance, hormone release and response, as well as the adipocyte cell proliferation. Therefore, the objective of this work is to review the current knowledge about the influence of ion channels in obesity development. This review used different sources of literature (Google Scholar, PubMed, Scopus, and Web of Science) to assess the role of ion channels in the pathophysiology of obesity. Ion channels present diverse key functions, such as the maintenance of physiological homeostasis and cell proliferation. Cell biology and pharmacological experimental evidences demonstrate that proliferating cells exhibit ion channel expression, conductance, and electrical properties different from the resting cells. Thereby, a large variety of ion channels has been identified in the pathogenesis of obesity such as potassium, sodium, calcium and chloride channels, nicotinic acetylcholine receptor and transient receptor potential channels. The fundamental involvement of these channels on the generation of obesity leads to the progress in the knowledge about the mechanisms responsible for the obesity pathophysiology, consequently emerging as new targets for pharmacological modulation.

Keywords: energetic metabolism, food intake, adipose cells, ion channels, obesity

INTRODUCTION

Obesity is an important disease associated to the excessive accumulation of body fat, leading to weight gain and the development of chronic disorders, including arterial hypertension, type 2 diabetes mellitus, dyslipidemias, sleep apnea, and cancer (Jeffreys et al., 2003; Van Gaal et al., 2006; Pischon et al., 2008; Whitlock et al., 2009; Vucenik and Stains, 2012; Singh et al., 2013). Currently, it affects 35% of adults aged 20+ with a rising prevalence (World Health Organization [WHO], 2014).

Multiple factors are involved in the origin of this disease, involving genetic determinants, as well as environmental, psychosocial and psychobiological factors (Comuzzie and Allison, 1998; Bocchieri et al., 2002; Noll et al., 2007). Meanwhile, regardless of its cause, the body weight results from a complex interaction between physio- and psychological components that control food intake and energy expenditure (Martinez, 2000).
Food intake is regulated centrally and it is influenced by the phenomena of hunger, satiety and appetite. Neurons located in several regions of the hypothalamus (ventromedial, lateral hypothalamic, arcuate and paraventricular nuclei) and in extra hypothalamic regions, including hindbrain (nucleus tractus solitarii), midbrain (ventral tegmental area) and forebrain (nucleus accumbens), are associated with the energetic homeostasis in human (Thaler et al., 2013).

Specifically, the arcuate nucleus (ARC) in the mediobasal hypothalamus contains different types of neurons correlated to the expression of orexigenic peptides, such as neuropeptide Y (NPY) and agouti-related peptide (AgRP), which stimulate food intake and reduce the body energy expenditure. In contrast, neurons expressing anorexigenic peptides derived from pro-opiomelanocortin (POMC), cocaine and amphetamine regulated transcript (CART) trigger opposite effects, such as decreased food intake and increased body energy expenditure (Bing et al., 1996; Schwartz et al., 2000; Broberger, 2005; Huda et al., 2006). In addition, the nucleus tractus solitarii (nTS) receives gustatory and visceroreceptive signals, especially from vagal afferents synapse, and sends projections to different brain regions in order to regulate the food intake (Harding and Leek, 1973; Appleyard et al., 2005). Recently, several studies have suggest a role of ion channels in the regulation of synaptic function in the brain associated to the increase/decrease of expression of orexigen/anorexigen peptides and the energetic homeostasis (Olds and Xu, 2014).

The energetic balance has also multiple periphery influences, mainly the blood glucose levels, neurotransmitters, adipokines and cytokines, such as the hormones involved in glucose metabolism (adiponectin and resistin), inflammation [tumor necrosis factor-α (TNF-α) and interleukin 6 (IL6)], coagulation [plasminogen activator inhibitor type-1 (PAI-1)], blood pressure (angiotensinogen and angiotensin II) and feeding behavior (leptin and ghrelin), which are responsible for the obesity progression (Chu et al., 2001; Yamauchi et al., 2001; Vendrell et al., 2004; Ran et al., 2006; Ohashi et al., 2014). Therefore, peripherally released hormones can regulate the development of obesity throughout the modulation of central events.

Leptin is a key adipokine in the regulation of energy intake/expenditure that shows concentrations proportional to body fat mass (Sinha and Caro, 1998). Leptin acts on the ARC stimulating the anorexigenic neurons and inhibiting the orexigenic ones (Druce and Bloom, 2006). Another important event promoted by this adipokine is the induction of post-translational processing of the precursor molecule of POMC, leading to the production of melanocortin peptides that present anorexigenic property (Broberger, 2005). Mutations affecting the leptin-melanocortin pathway involving genes encoding leptin and/or its receptor and the prohormone convertase enzyme that process the POMC constitute the more present genetic alterations in obese (Faroogi and O’Rahilly, 2008). Ghrelin is produced in the stomach (Tschop et al., 2000; Wiedmer et al., 2007) and is the only peripheral hormone that stimulates the expression of orexigenic neuropeptides. Thus, it is known to induce increase in hunger and food intake (Huda et al., 2006). Before meals, the levels of ghrelin are raised, and after the ingestion of nutrients, its levels are suppressed (Tschop et al., 2001). Additionally, adiponectin is a hormone which is synthesized, exclusively, by adipocytes and acts inhibiting the hepatic glucose production, while increasing glucose uptake in muscle, as well as the oxidation of fatty acids in the liver and muscles, causing energy expenditure (Scherer et al., 1995; Kadowaki and Yamauchi, 2005). Therefore, obese individuals present low levels of adiponectin (Lindsay et al., 2002; Hajer et al., 2007).

The adipose tissue has the ability to store excess calories resulting in the process of hypertrophy and/or hyperplasia (Ferranti and Mozaffarian, 2008). The deposition and release of fatty acids from adipose tissue (as triglyceride) alters the food intake and energy expenditure. Moreover, different studies showed that adipose tissue is generally composed by 50% of adipocytes and the remaining 50% are cells such as preadipocytes, vascular cells, neural, leukocytes and cells of the immune system (Gustafson, 2010; Maenhaut and Van de Voorde, 2011). Based on functional and morphological differences, this tissue was divided into two main types, white adipose tissue (WAT) and brown adipose tissue (BAT). The WAT acts as an energy storage and is an active endocrine organ, releasing the free fatty acids and adipokines. Conversely, the BAT presents cells which are characterized by multilocular lipid droplets and an increased number of mitochondria, which express uncoupling protein 1 (UCP1), which uncouples the rates of substrate oxidation and ATP production by favoring a loss of protons and thus energy release. Thus, BAT is associated with thermogenesis (Tam et al., 2012).

Regarding the diagnosis of obesity, anthropometric criteria are the most often used, such as body mass index (BMI), measurement of waist circumference, waist-hip ratio, and skinfold test with the use of tweezers to evaluate the percentage of fat (Racette et al., 2003; McArdle et al., 2008). Additionally, there are other techniques for the assessment of body weight, including electrical bioimpedance (BIA), hydrostatic weighing and dual-energy X-ray absorptiometry (DEXA): BIA evaluates the resistance to a low frequency electrical current, considering that the current travels through the aqueous compartments and not through the greasy ones, where the flow impediment occurs (Kushner and Schoeller, 1986). The hydrostatic weighing determines the total volume of the body by analyzing the difference between the weight of an object in water and air, determining the density of the whole body (Schoeller et al., 1980). In DEXA analysis, the composition of soft body tissues is measured, by using the ratio of absorption of X-rays of different energies attached to adipose tissue mass (Kohrt, 1998).

Obesity treatment is based on multiple approaches that may encourage behavior change in long term, through energy-reduced diets, physical activity and/or exercise, pharmacotherapy and surgery (National Institutes of Health [NIH], 1991, 2000; Rosenbaum et al., 1997; Klein, 1999; Bray and Tartaglia, 2000). There is a consensus among the National Institutes of Health, the National Heart, Lung and Blood Institute and the North American Association for the Study of Obesity that the choice of treatment depends on the degree of obesity and the presence of comorbidities. Accordingly, for BMI ≥ 25 kg/m², changes in...
lifestyle are recommended (physical activity, diet, and behavior), for BMI into 27.7–29.9 kg/m², in the presence of comorbidities or for BMI ≥ 30 kg/m², in the absence of comorbidities, the use of pharmacotherapy is recommended. The surgery for weight reduction is recommended for patients with severe obesity (BMI > 35 kg/m²) in the presence of comorbidities, or individuals with BMI > 40 kg/m² in the absence of comorbidities (National Institutes of Health [NIH], 2000).

Nowadays, the treatment of obesity remains a challenge. Most anti-obesity drugs currently prescribed target appetite regulation or decreasing in the absorption of nutrients (Bays, 2004). Most of them have significant side effects, and do not act specifically on regulatory functions of appetite in the hypothalamus, but exhibit a broad spectrum of actions. In many cases, beneficial effects remain limited (Heymsfield et al., 1999).

The most prescribed drugs for the treatment of obesity are sibutramine (serotonin and norepinephrine reuptake inhibitor) and orlistat (gastrointestinal lipase inhibitor), both prescribed for long-term use (Cannon and Kumar, 2009). The use of sibutramine for weight reduction has favorable effects on risk factors for cardiovascular disease (increasing high-density lipoprotein and decreasing levels of cholesterol and triglycerides in the blood; Dujovne et al., 2001). However, the use of this drug is contraindicated in patients with uncontrolled hypertension, coronary artery disease, cardiac arrhythmias, congestive heart failure or stroke, because it can increase blood pressure and heart rate (Kim et al., 2003). It is recommended the use of orlistat associated with multivitamin supplements, considering that orlistat affects the absorption of fat-soluble vitamins (A, D, E, and K) that are essential for the body (Cannon and Kumar, 2009). In obese patients, the benefits of this drug use is associated with lower incidence of type 2 diabetes, reduction of total cholesterol, LDL cholesterol and triglyceride levels as well as the levels of glycated hemoglobin (HbA1c) in diabetic (Aronne et al., 2009). Amfepramone (diethylythionine) and fenproporex are also inhibitors of appetite, which act on the hypothalamic neurons, increasing the release of norepinephrine and stimulating the noradrenergic receptors, then, inhibiting hunger (Zaragoza et al., 2005; Cohen, 2009). Other medications have been evaluated in obese individuals, however, without formal indication for obesity treatment.

Because of ethical limitations on studying the susceptibility of human obesity, animal models of obesity has been proposed to investigate the pathophysiological changes caused by this disease (Pereira et al., 2003). Obesity has been induced in animals by nerve injury, endocrine disorders, genetic, and/or dietary modifications (Sclafani and Springer, 1976), which facilitates the study of the pathophysiology of obesity and allows advances in the development of new therapies.

Therefore, in view of the influence of obesity in the development of chronic diseases affecting the life expectation and the limitations of the current available treatment, this revision focused on the involvement of ion channels in the pathophysiology of obesity, as well as the role of these targets as new approaches toward the development of new anti-obesity drugs.

ION CHANNELS IN THE DEVELOPMENT OF OBESITY

Ion channels play fundamental roles in diverse key functions, such as maintenance of physiological homeostasis, cell proliferation and signal transduction in a variety of cell types and different cell stages (Nilius and Droogmans, 2001; Chen et al., 2007). Cell biology and pharmacological experimental evidences demonstrate that proliferating cells exhibit ion channel expression, conductance, and electrical properties which are very different from the resting cells (Conti, 2007). In this context, the investigation of ion channels has been emerging as a new approach in the study of the pathogenesis of obesity.

Ion Channels on Adipose Cell Proliferation

Obesity development results from the expansion of WAT and this process depends of stem cell proliferation (Gray and Vidal-Puig, 2007). This process is dependent of ion channels functionality (Chen et al., 2007). It is well-known that K⁺ channels are involved in cell proliferation, as the EGF-mediated mitogenic signal transduction process, required for voltage-gated K⁺ channels participating in G1/S-phase transition of the cell cycle (MacFarlane and Sontheimer, 2000). Previous studies reported the presence of voltage-gated K⁺ currents (KV) in BAT isolated from the interscapular fat pads of neonatal rats (Lucero and Pappone, 1989; Russ et al., 1993), WAT differentiated from rats (Ramirez-Ponce et al., 1996) and/or human preadipocytes (Ramirez-Ponce et al., 2003). Additionally, Bai et al. (2007) identified three types of K⁺ currents on human adipose tissue-derived stem cells (hASCs): a delayed rectifier-like K⁺ current (IKDR), a Ca²⁺-activated K⁺ current (IKCa) and a transient outward K⁺ current (Ito). In addition, the mRNA of Kv1.1, Kv1.5, Kv2.1, Kv7.1, Kv10.1, and Kv11.1 has been shown to correspond to IKDR, mRNA of MaxiK (BKCa), KCNN3 (SKCa3) and KCNN4 (SKCa4), corresponding to IKCa, and high mRNA levels of Kv1.4, Kv4.2, and Kv4.3, contributing to Ito. However, despite the expression of these different K⁺ channels in hASCs, only the IKDR current has been associated to its proliferation (Table 1).

Hu et al. (2009) showed the crucial participation of K⁺ channels in obesity. The knockdown or blockade of 4-aminopyridine and paxilline of KCa1.1 and Kv4.2 channels, respectively, related to Ito, increased the cell number of human preadipocytes on G0/G1 phase, preventing cell cycle progression. Thus, these data indicate the importance of K⁺ channels activity to preadipocytes proliferation and differentiation, resulting in obesity installing. Additionally, in brown adipocytes culture obtained from rat, it has been demonstrated that the blockade of Kv channels with tetraethylammonium inhibits cell proliferation (Pappone and Ortiz-Miranda, 1993). The brown adipocytes are connected to metabolic energy expenditure and, therefore, are important to prevent fat accumulation. Thus, a balance in the activity of white and brown fat cells can be seen, regulated by K⁺ channels, that prevent fat deposition. It
is still not clear the role of K⁺ channels in the genesis of obesity. The data presented here ponder a similar role of these channels on the proliferation of both white and brown preadipocytes. It becomes important, therefore, to determine which of these subtypes are predominant for the evolution of the cell cycle in those two cell types and how its dysfunction would lead to the development of obesity (Table 1).

Other ion channels have been associated with proliferation of preadipocytes. On 3T3-L1-preadipocytes, an establish a model for adipocyte differentiation, and visceral adipose tissue from both mice and human, Zhang et al. (2007) have detected the expression of TRPV1 and have shown that TRPV1 are important in preventing the proliferation and differentiation of preadipocytes. Accordingly, the treatment with capsaicin, a TRPV1 agonist, prevented the differentiation of these cells. Likewise, it has been evidenced the TRPV1 downregulation during adipogenesis of preadipocytes as well as on visceral adipose tissue from db/db and ob/ob mice, suggesting that TRPV1 function prevents adipogenesis and consequently obesity (Miller et al., 1996; Neal and Clipstone, 2002) (Table 2). Additionally, Hu et al. (2010) have detected Cl⁻ currents on human subcutaneous adipose tissue. Furthermore, it was verified the expression of chloride channel-3 (CIC-3) on this tissue and its blockade with tamoxifen reduced cell proliferation, suggesting the role of Cl⁻ channel in regulation of human preadipocyte proliferation.

Therefore, all these data directs to a probable requirement for hyperpolarized state of preadipocytes, which can be achieved by the efflux of K⁺, inhibition of cation influx or even by Cl⁻ influx, to the progress of these cells in the cell cycle until reaching the needed maturity state for their proliferation and differentiation. Accordingly, drugs that prevent this progression by acting on ion channels involved could provide new tools for obesity therapy.

### Ion Channels on Central Food Intake Control

Some K⁺ channels have been shown to have an important role in the central regulation of food intake, energy expenditure, and glucose metabolism. The K<sub>ATP</sub> pore-forming subunit (Karschin et al., 1998; Zawar et al., 1999; Miki et al., 2001), is expressed in neurons of ventromedial hypothalamic nucleus (VMH), POMC and melanin-concentrating hormone (MCH) neurons of lateral hypothalamic area (LHA) of mice and mediates neuronal glucose-excitation, acting as a glucose sensor during feeding. The defective K<sub>ir</sub>6.2 prevents ATP-mediated K<sub>ATP</sub> blocking, leading to impaired glucose responsiveness by POMC neurons, resulting in glucose intolerance (Sohn, 2013). Additionally, this event has been observed in obese mice on a high-fat diet, resulting in loss of glucose sensitivity by these neurons, contributing to food intake overstimulation and obesity progress (Miki et al., 2001). These data corroborate Rowe et al. (1996), who showed that obese rats exhibit abnormal electrophysiological responses in hypothalamic glucose-sensors neurons to changes on extracellular glucose concentration, whereas lean rats respond normally. The role of K<sub>ATP</sub> on regulating food intake behavior has been also shown to be important in preventing age-dependent obesity. It was shown that rapamycin-sensitive (mTOR) signaling is elevated in POMC neurons of old mice, causing silencing of these neurons and inhibition of leptin-induced release of the anorexigenic α-MSH, associated with upregulation of K<sub>ATP</sub> channel activity and an aging-dependent high expression of K<sub>ir</sub>6.2 (Yang et al., 2012) (Table 1).

### Table 1 | Characterization of K⁺ channels associated to obesity.

| Localization                          | Species | K⁺ channel subtype (gene) | Comments                                      | Reference                    |
|---------------------------------------|---------|---------------------------|-----------------------------------------------|------------------------------|
| Subcutaneous preadipocytes            | Human   | K<sub>v</sub>1.1 (KCNV1)  | Promote preadipocytes proliferation           | Bai et al., 2007; Hu et al., 2009 |
|                                       |         | K<sub>v</sub>1.5 (KCNV5)  |                                               |                              |
|                                       |         | K<sub>v</sub>2.1 (KCNN1)  |                                               |                              |
|                                       |         | K<sub>v</sub>7.1 (KCNN1)  |                                               |                              |
|                                       |         | K<sub>v</sub>10.1 (KCNN1) |                                               |                              |
|                                       |         | K<sub>v</sub>11.1 (KCNN2) |                                               |                              |
|                                       |         | K<sub>v</sub>11.1 (KCNN4) |                                               |                              |
|                                       |         | K<sub>v</sub>12.2 (KCNN2) |                                               |                              |
| Brown adipocytes                      | Rat     | K<sub>ir</sub>6.2 (Kcnj17) | Associated with adipose cells proliferation  | Pappone and Ortiz-Miranda, 1993 |
| Central nervous system                | Mice    | K<sub>2P</sub>K<sub>3</sub> (Kcne2, 7) | Mediates the glucose-sensitive neuronal excitation and regulates food intake | Miki et al., 2001; Sohn, 2013 |
|                                       |         | K<sub>2P</sub>K<sub>9</sub> (Kcne1, 3) | Activated by high glucose levels and inhibits orexin/hypocretin release | Burdakov et al., 2006 |
|                                       |         | K<sub>2P</sub>Ca<sub>1.3</sub> (Kcne2, 7) | Regulation of energy homeostasis, body weight, and insulin resistance | Xu et al., 2003, 2004 |
|                                       | Rat     | K<sub>v</sub>3.1 (Kcnj1)  | Regulates response of taste cells to fat ingestion and the leaning to high fat intake | Gilbertson et al., 2005 |

---

**Frontiers in Pharmacology | www.frontiersin.org**
Leptin and insulin are well-recognized as anorexigenic hormones released from adipocytes and pancreatic beta cells, respectively (Williams et al., 2011b). Typically, leptin activates POMC neurons and leptin receptor (Lepr)-expressing neurons of ventral premammillary nucleus (PMV), known to release of anorexigenic hormones (Cowley et al., 2001; Al-Qassab et al., 2009; Williams et al., 2010, 2011a). However, their effects on ion channels in the CNS are yet controversial. In the VMH, insulin receptors expressed by the SF-1 neurons activate K_{ATP} channels and suppress steroidogenic factor 1 (SF1) neuron activity, which resulted in diet-induced obesity (Klockener et al., 2011). In addition, insulin activates some arcuate NPY/AgRP neurons, which release orexigenic hormones, leading to hyperphagia state (Al-Qassab et al., 2009). Melanocortin is another hormone important in regulating body fat accumulation. Mutations on MC4R has been shown to induce obesity in rodents and humans (Huszar et al., 1997; Vaise et al., 1998; Tallam et al., 2005), and its activation hyperpolarizes parasympathetic preganglionic neurons in brainstem via PKA-dependent activation of tolbutamide-sensitive K_{ATP} channels and depolarize the sympathetic ones, which could be one of the factors responsible to inducing obesity-associated hypertension. However, this data is more associated with an obesity consequence than a cause. The ion channels involved in melanocortin pathways to regulate food intake and obesity development have not yet been determined. Therefore, the effects of these hormones on ion channels activity in neurons that regulate food intake deserve an interesting focus for future insights attempting to better understand their relationship with obesity. Meanwhile, K_{ATP} channels appear to be promising targets to treatment of obesity, focusing in drugs acting in CNS neurons regulating food intake (Table 1).

K_{V}1.3 has been implicated in the regulation of energy homeostasis, body weight and insulin resistance (Xu et al., 2003, 2004). This channel was shown to act as a metabolic sensor responding to insulin levels in mitral cells of olfactory bulb, and its removal increases the weight gain (Marks and Fadool, 2007; Biju et al., 2008). Mitral cells of the olfactory bulb function as internal chemical sensors of metabolic state by modulating K_{ATP} channels predominantly expressed in these neurons (Fadool et al., 2000). K_{V}1.3 knockout mice fed a high-fat diet exhibit increased light-phase metabolism in addition to reduced weight gain, reduced levels of sugar, leptin and insulin in the blood, and increased energy expenditure (Xu et al., 2003, 2004; Li et al., 2006; Tamura et al., 2012).
Tucker et al., 2008; Fadool et al., 2011; Tucker K. et al., 2012; Tucker K.R. et al., 2012). Additionally, these knockout exhibited metabolic alterations including increase in energy expenditure and locomotor activity, resistance to diet- and genetic-induced obesity and increased insulin sensitivity (Fadool et al., 2004; Xu et al., 2004; Tucker et al., 2008). Therefore, linking to the role of KATP channels in hypothalamic areas to regulate food intake, the Kv1.3 channels seem to have an important role at the CNS too. These channels appear to be important in regulating food drive through the olfactory effects which are responsible for stimulating food intake (Table 1).

Nicotinic receptors have been shown to have an important role to prevent fat accumulation and to induce fat degradation. In a model of type 2 diabetes, the homozygous leptin-resistant db/db obese mouse, Marrero et al. (2010) measured the effects of a novel α7 nAChR-selective agonist, TC-7020, and showed reduction of food intake and weight gain. These parameters were reversed by using a janus kinase 2 (JAK2) specific inhibitor (AG-290), demonstrating that the α7 nAChRs plays an important role in the body weight control and it involves JAK2 signal transducer and activator of transcription 3 (STAT3) signaling pathways. Similarly, C57BL/6J mice with a high-fat diet treated with galantamine, an acetylcholinesterase (AChE) inhibitor that enhances cholinergic signaling and also acts as a positive allosteric modulator of α7 nAChR, presented reduction on food intake and body weight and abdominal adiposity as well as an improvement on blood glucose, insulin resistance, and hepatic steatosis (Satapathy et al., 2011) (Table 3).

Cigarette smoking habits have been associated with less body fat distribution, body weight, insulin resistance and obesity (Chiolero et al., 2008; Clair et al., 2011). Indeed, the smoking cessation increases body weight (Perkins, 1993). Experimentally, nicotine administration to rodents and humans suppresses appetite, increases energy expenditure and alters feeding behavior (Jo et al., 2002; Fornari et al., 2007; Zoli and Picciotto, 2012). The mechanisms involved in nicotine-induced decrease in body weight have been correlated to both central and peripheral nicotinic cholinergic signaling. In CNS, nAChRs composed by both α7 and α/β subunits were detected throughout areas of the hypothalamus that regulate appetite, food consumption and body mass. In previous studies, it was revealed from moderate to high levels of α4, α7, and β2-mRNAs in hypothalamus, with particularly prominent expression in the supraoptic or suprachiasmatic nuclei and lateral hypothalamus (Jo and Role, 2002). Moreover, although the α3β4 nAChR is the predominant nicotinic receptor in the peripheral nervous system, it is less widely distributed in the rat brain (Dwyer et al., 2008) and has been related to nicotine effects on mice hypothalamus to decrease food intake. In particular, the activation of α3β4 nAChRs in POMC cells in the ARC decreases food intake and increases energy expenditure (Williams and Schwartz, 2005; Mineur et al., 2011) (Table 3).

The gamma-aminobutyric acid type A receptor (GABA_A) has been associated to the body weight regulation. Tong et al. (2008) showed that inhibition of GABA release from AgRP neurons of mice prevents obesity. Additionally, Vong et al. (2011) showed a lean phenotype in the presence of defective synaptic release of GABA from NPY/AgRP neurons. This effect was associated to a decrease on inhibitory post-synaptic currents (IPSCs) in anorexigenic POMC neurons. Beyond this, Wu et al. (2009) have showed that inhibition of GABA_A receptor with the antagonist

### Table 3 | Characterization of nAChRs associated to obesity.

| Localization          | Species | nAChRs (gene) | Comments                                      | Reference                  |
|-----------------------|---------|---------------|-----------------------------------------------|----------------------------|
| Central nervous system| Human   | α7 (CHRNA7)   | Associated to the energetic metabolism regulation | Jo et al., 2002            |
|                       |         | α/β (CHRNA1, 2, 3, 4, 5, 6, 9, 10 and CHRNB1, 2, 3, 4) |                               |                            |
| Rat                   |         | α3 (Chma3)   | Distributed in both the peripheral and central nervous system. Associated to food intake regulation | Dwyer et al., 2008         |
|                       |         | β4 (Chnrb4)  |                                               |                            |
| Mice                  |         | α4,7 (Chma4, 7) | Express in hypothalamus regulating appetite, food consumption, and body mass | Jo and Role, 2002          |
|                       |         | β2 (Chnrb2)  | Regulates food intake                          | Mineur et al., 2011        |
|                       |         | α3 (Chma3)   |                                               |                            |
|                       |         | β4 (Chnrb4)  |                                               |                            |
| Adipose tissue        | Human   | α7 (CHRNA7)   | Gene expression is reduced in obese individuals | Cancello et al., 2012       |
|                       |         | α2 (CHRNA2)   | Gene expression is associated with obesity/obesity | Kim, 2008                  |
|                       |         | α3–5 (CHRNA3,4,5) | Associated to alteration on BMI               | Freetathy et al., 2011; Zhu et al., 2013 |
|                       |         | α3, 5 (CHRNA3,5) | Associated to abdominal obesity              | Zhu et al., 2014           |
|                       |         | β3, 4 (CHRNB3,4) |                                               |                            |
| Rat                   |         | α1–7, 9, 10 (Chma1, 2, 3, 4, 5, 6, 7, 9, 10) | Promote nicotine-induced adipocytes adiponectin and FFA release | Liu et al., 2004           |
|                       |         | β1–4 (Chnrb1, 2, 3,4, 5 (Chmrd) |                                               |                            |
|                       |         | α2 (Chma2) | Alterations in lean body mass and fat storage | Somm et al., 2014          |
|                       | Mice    | β1–2 (Chmb1,2) |                                               |                            |
bicuculline, in the parabrachial nucleus (PBN), a region that regulates taste reactivity (Higgs and Cooper, 1996), decreases the feeding and increases the loss of body weight. Thus, there are evidences linking the inhibitory effect of GABA_A receptors in anorexigenic hypothalamic neurons that may be responsible for promoting obesity development.

Monosodium glutamate has been shown to cause hypothalamic damages (Kaufhold et al., 2002) and the chronic overconsumption of the aminoacid glutamate (GLU) promotes obesity (Hermanussen and Tresguerres, 2003). In this view, the selective GLU-gated calcium channels antagonist, memantine, has been reported to display neuroprotective effects. Additionally, obese young women since childhood or after the first pregnancy treated with memantine presented protection on physiological regulation of appetite affected by high nutritional GLU, as well as being led to marked body weight reduction within a few days (Hermanussen and Tresguerres, 2005). Probably activation of Ca^{2+} channels in the hypothalamus, such as that produced by glutamate on its ionotropic NMDA-R, promotes release of orexigenic hormones, affecting the nutritional status and triggering obesity. However, more works in this field should be conducted to better characterize the role of these ion channels.

**Ion Channels on Sleep-Vigilant Cycle Dysfunction-induced Obesity**

There are few studies linking sleep and metabolism, being this interplay only currently receiving attention. In a study made by Uebele et al. (2009) using mice with deletion of Cav3.1 channels (Cacna1g KO mice), a model that promotes fragmented sleep, the potential link between sleep and obesity was investigated. The authors found that KO mice presented less weight gain and amount of fat after inducing them to a high-fat diet (HFD), compared to the wild type mice (WT). Moreover, it was showed that the resistance on weight gain observed to KO mice was due to metabolic rate changes in these animals, in a manner that did not affect core body temperature. Furthermore, the authors assessed a possible similar effect using a T-type Ca^{2+} channel antagonist (TTA-A2) and, initially, they observed that the inhibition of T-type Ca^{2+} of WT mice caused sedation and decreased on active wake, consistent with altering thalamocortical neuronal activity. Additionally, these WT mice presented less weight gain after inhibition of T-type Ca^{2+} and, interestingly, this difference was observed only when the mice received HFD. All the results were similar to that observed on Cacna1g KO mice. Additionally, animals fed with HFD presented reduced food intake, not on the active phase, but in the inactive phase. These effects probably result from a better alignment of diurnal feeding patterns with daily changes in circadian physiology and, potentially, an increased metabolic rate during the active phase. Thus, these data suggest a role for Cav3.1 in co-regulating sleep and weight maintenance and data from pharmacological studies demonstrate that potent and selective T-type calcium channel antagonists reduce– wakefulness, diet-induced weight gain, and improve- body composition, suggesting this ion channel class may provide a novel therapeutic target for the treatment of obesity.

Additionally, it has been shown that elevated glucose levels, reached, e.g., after meal, activate a two-pore domain K^{+} channel (K2P) and inhibits orexin/hypocretin release by LHA neurons, regulating the sleep-vigilant cycle (Burdakov et al., 2006). Thus, impaired K2P function can emerge as a reason of hyperphagia promoted by release of high amounts of this hormone associated with sleep-vigilant cycle dysfunction (Table 1).

Therefore, there must be an interplay between Ca^{2+} and K^{+} channels that regulates sleep-vigilant cycle and food intake as well, emerging as interesting targets in the CNS to treat obesity, especially the sleeplessness.

**Ion Channels on Peripheral Food Intake Control**

Free fatty acids are able to activate peripherally taste receptor cells (TRCs; Fukuwatari et al., 2003), the stimulus involves an interaction between the tautant and ion channels or receptors localized in most cases on the apical membranes of the TRCs. The initial events in the taste transduction of free fatty acids include an inhibition of delayed rectifying potassium channels (DRK) associated with Kv3.1 channels (Gilbertson et al., 1997, 1998, 2005). Gilbertson et al. (2005) have demonstrated that DRK currents are inhibited in obese-resistant rats (O-R), but not in obesity-prone (O-B) test cells, in response to polyunsaturated fat acids (PUFAs), and this effect was associated with the greater activation of taste cells in O-R than that in O-B. Additionally, TRCs in O-R would be activated to a greater degree by PUFAs than those from O-B. Likewise, the DRK channels were not found in O-R, indicating that PUFAs do not inhibit K^{+} currents by these channels in O-B, and they are the most responsible for the taste cells inhibition in obese rats, which might explain the preference of these obese rats to a high fat dietary, while the resistant-rats tend to eat much less (Table 1).

**TRPM5** is another ion channel abundantly identified in TRCs which participates in sweet, umami, and bitter perception. The disruption of this channel gene in mice abolishes the transduction of these tastes (Pérez et al., 2002; Zhang et al., 2003). TRPM5^{−/−} mice were shown to present the same pattern of food intake and gained less weight than wide-type mice when fed a high-sugar diet, being this effect probably due to the loss of sucrose preference (Glendinning et al., 2012). Interestingly, these data corroborate Gilbertson et al. (2005), as showed previously, that demonstrated that inhibited state of taste cells leads to obesity sensitivity. Additionally, TRPM5^{−/−} mice also abolished the preference for fat and reduced the fatty acid-induced [Ca^{2+}]; increase, suggesting that TRPM5 also plays a key role in lipid taste perception (Oike et al., 2006; Sclafani et al., 2007; Liu et al., 2011) (Table 2).

**Ion Channels on Body Energetic Expenditure**

Some ion channels have been associated with the regulation of energetic expenditure. The nicotinic cholinergic signaling, in
special, in metabolic tissue, is one of them. Liu et al. (2004) have shown that α1−7, 9−10, β1−4, δ and ε subunit mRNAs are expressed in rat adipocytes, and the release of FFA by this cell has been known to increase nicotine concentration. Recent studies of Somm et al. (2014) have shown that in mouse WAT, α2 and β1 were the most expressed nAChR subunits. Meanwhile, mouse BAT expresses α2 and comparable amounts of β1 and β2 nAChR subunits. Then, although in a α7β2 nAChR(−/−) mice model it was verified the unaltered body weight, a decreased fat storage was observed. Additionally, Canello et al. (2012) have demonstrated the expression of α7 nAChR in isolated mature adipocytes and human subcutaneous adipose tissue (SAT). Meanwhile, the expression of this receptor was associated with decreased SAT obtained from obese human compared to normal-weight human. In addition, α7 nAChR had 75% lower expression in mature adipocytes isolated from morbidly obese human compared to adipocytes from normal-weight human. These receptors modulates inflammatory gene expression in human adipocytes and are linked to adipocyte lipid catabolism (Table 3).

In human studies, polymorphisms in genes encoding nAChRs have been focused to examine the potential involvement of nicotinic receptors variants on the distribution of body fat. The SNP in the nAChR α2 subunit gene (CHRNA2) was associated with overweight/obesity (Kim, 2008). There was no association between the BMI and the genotype of 15q25 SNP (CHRNA5–CHRNB4 gene region) in the never smokers, however, there was no association between the BMI and the genotype of 15q25 SNP in the nAChR α2 subunit gene (CHRNA2) was associated with overweight/obesity (Kim, 2008). Interestingly, FAS activity has been prevented by Ca2+ channel blockade with nifedipine (Zemel et al., 1995). Interestingly, FAS activity has been prevented by Ca2+ channel blockade with nifedipine (Jones et al., 1996). Moreover, it was reported that chronic hyperinsulinemia induces an increase in FAS mRNA level and activity in both rat liver and WAT (Chakrabarty and Leveille, 1969). In this context, Kim et al. (1996) reported that treatment of obese mice with nifedipine normalized both FAS mRNA and plasma insulin levels, associated with a reduction of fat pad mass in agouti-induced obese mice, together with an increase in the skeletal muscle weight increase, which can be associated with the use of energy from adipose store by muscle cells. Indeed, it was also observed that the treatment corrected the reduction in core temperature of obese mice, which can be explained by the increase in energy expenditure by skeletal muscle. This effect was associated with a possible reduction on Ca2+ levels on pancreatic β-cells, reducing the insulin secretion, or due to an improvement in insulin sensitivity on these mice. Alternatively, it is not discarded that Ca2+ can acts in transcriptional level to increase the FAS expression. Therefore, nifedipine was able to reduce lipogenesis and insulin resistance in obese mice. Early evidence has already been reported, according to which the anti-obese effect of a Ca2+ channel blocker, benidipine, which reduced mice body weight associated with the increase in blood flow to BAT, functions as the main thermogenic organ (Yoshida et al., 1994).

Together, these data bring interesting information regarding nicotinic, TRPs and calcium channels as key ion channels responsible for regulating energy expenditure. Therefore, new drugs targeting these channels could emerge as new approaches in the field of obesity treatment.

### Ion Channels on Accelerated Gastric Emptying Leading to Overeating

The accelerated gastric emptying and thus reduced nutrient absorption has been linked with food overconsumption and obesity development. Nozawa et al. (2009) have showed the expression of TRPA1 in the gastrointestinal tissues and...
enterochromaffin cells (ECs) in humans, mice, and rats. The stimulation of TRPA1 by allyl isothiocyanate (AITC) and cinnamaldehyde increased 5-hydroxytryptamine (5-HT) release from EC cells, which is known to accelerate the gastric emptying in human and it is known to the overconsumption on a HFD and subsequent obesity (Wright et al., 1983; Zahorska-Markiewicz et al., 1986; Tosetti et al., 1996) (Table 2). Furthermore, there are reports suggesting that gastric emptying of solid food is accelerated in obese subjects, which precipitates hunger and frequent eating (Wright et al., 1983; Tosetti et al., 1996). In obese humans, accelerated gastric emptying may be one of the contributing factors to overconsumption on a HFD and subsequent obesity (Wright et al., 1983; Zahorska-Markiewicz et al., 1986; Tosetti et al., 1996). In this context, Li et al. (2013) reported Ca\textsuperscript{2+} and K\textsuperscript{+} currents in antral circular smooth muscle cell. The diet-induced obese-prone rats exhibit accelerated gastric emptying attributed to a higher density of L-type Ca\textsuperscript{2+} currents (I_{\text{Ca,L}}) and inactivation or low density of K\textsuperscript{+} currents, being them the responsible for the high Ca\textsuperscript{2+} currents amplitude in these cells and thus increasing gastric emptying, leading to overconsumption and obesity.

**PERSPECTIVES**

In view of the large amount of information regarding the involvement of ion channels in the obesity development, as well as the development of suitable animal models, a new unexplored aspect arises to establish novel alternatives for obesity treatment having as targets deregulated molecular aspects in the genesis of this disease. Various ion channels have been identified in several cell types as important regulators of some functions related to the development of obesity. The K\textsuperscript{+} channels were the most well-studied and have been associated with the proliferation of adipose cells, central and peripheral regulation of food intake and gastric emptying time, all preponderant for the development of obesity. Other channels, such as TRPs and nicotinic receptors, are involved in many of these functions. The Ca\textsuperscript{2+} channels, although still not better explored, has been associated particularly in unusual obesity factors, such as disruption of the sleep-wake cycle, as well as chloride channels not yet explored, but identified in some cell types involved in obesity. In this sense, further research targeting important ion channels in the pathogenesis of obesity are promising for the development of more effective drugs to treat the disease. Accordingly, drugs that act on the ion channels described, specially K\textsuperscript{+} channels, may be promising to the further treatment of obesity.

**AUTHOR CONTRIBUTIONS**

LV, IS, and LP made the major part of research, designed and write the manuscript; BdS guided the preparation of the work.

**ACKNOWLEDGMENTS**

The authors thank CAPES (308452/2011-9) and CNPq (476692/2012-1) for financial support and UFPB for institutional support.
Clair, C., Chiòlero, A., Faeh, D., Cornuz, J., Marques-Vidal, P., Paccaud, F., et al. (2011). Dose-dependent positive association between cigarette smoking, abdominal obesity and body fat: cross-sectional data from a population-based survey. *BMC Public Health* 11:23. doi: 10.1186/1471-2458-11-23

Cohen, P. A. (2009). Imported fenproporex-based diet pills from Brazil: a report of two cases. *J. Gen. Intern. Med.* 24, 430–433. doi: 10.1001/jamainternmed.2009.387-4

Comuzzie, A. G., and Allison, B. B. (1998). The search for human obesity genes. *Science* 280, 1374-1377. doi: 10.1126/science.280.5366.1374

Conti, M. (2007). Targeting ion channels for new strategies in cancer diagnosis and therapy. *Curr. Clin. Pharmacol.* 2, 135–144. doi: 10.2174/157488407780598153

Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horváth, T. L., et al. (2001). Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. *Nature* 411, 480–484. doi: 10.1038/35078085

Dohara, H., Nozawa, K., Kawabata-Shoda, E., Kojima, R., Yokoyama, T., and Ito, H. (2009). TRPA1 agonists delay gastric emptying in rats through serotonergic pathways. *Naunyn Schmiedebergs Arch. Pharmacol.* 380, 353–357. doi: 10.1007/s00210-009-0435-7

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Dujovne, C. A., Zavoral, J. H., Rowe, E., and Mendel, C. M. (2001). *Druce*, M., and *Bloom*, S. R. (2006). The regulation of appetite. *Arch. Dis. Child.* 91, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759

Druce, M., and Bloom, S. R. (2006). The regulation of appetite. *Arch. Dis. Child. 91*, 183–187. doi: 10.1136/adc.2005.073759
Lindsay, R. S., Funahashi, T., Hanson, R. L., Matsuzawa, Y., Tanaka, S., Tataranni, Marks, D. R., and Fadool, D. A. (2007). Post-synaptic density 95 (PSD-95) affects Maenhaut, N., and Van de Voorde, J. (2011). Regulation of vascular tone by Marrero, M. B., Lucas, R., Salet, C., Hauser, T. A., Mazurov, A., Lippiello, P. M., Klockener, T., Hess, S., Belgardt, B. F., Paeger, L., Verhagen, L. A., Husch, A., Am. J. Clin. Nutr. Kawabata, F., Inoue, N., Yazawa, S., Kawada, T., Inoue, K., and Fushiki, T. (2006). Vasconcelos et al. Ion Channels in Obesity humans. Chem. Senses and capsaicin on energy balance: critical review and meta-analyses of studies in Koogan. J. Pharmacol. Exp. Ther. 310, 52–58. doi: 10.1124/jpet.103.065037 Klockener, T., Hess, S., Belgardt, B. F., Paeger, L., Verhagen, L. A., Husch, A., et al. (2011). High-fat feeding promotes obesity via insulin receptor/PIK3-dependent inhibition of SF-1 VMH neurons. Nat. Neurosci. 14, 911–918. doi: 10.1038/nn.2847 Kohrt, W. M. (1998). Preliminary evidence that DEXA provides an accurate assessment of body composition. J. Appl. Physiol. 84, 372–377. Kushner, R. F., and Schoeller, D. A. (1986). Estimation of total body water by bioelectrical impedance analysis. Am. J. Clin. Nutr. 44, 417–424. Kusudo, T., Wang, Z., Mizuno, A., Suzuki, M., and Yamashita, H. (2012). TRPV4 deficiency increases skeletal muscle metabolic capacity and resistance against diet-induced obesity. J. Appl. Physiol. 112, 1223–1232. doi: 10.1152/japplphysiol.01070.2011 Li, G. R., Deng, X. L., Sun, H., Chung, S. S., Tse, H. F., and Lau, C. P. (2006). Ion channels in mesenchymal stem cells from rat bone marrow. Stem Cells 24, 1519–1528. doi: 10.1634/stemcells.2005-0307 Li, S., Maude-Griffin, R., Pullan, A. J., and Chen, J. D. Z. (2013). Gastric emptying and Ca2+- and K+ channels of circular smooth muscle cells in diet-induced obese prone and resistant rats. Obesity 21, 326–335. doi: 10.1002/ob2021 Lindsay, R. S., Funahashi, T., Hanson, R. L., Matsuzawa, Y., Tanaka, S., Tataranni, P. A., et al. (2002). Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360, 57–58. doi: 10.1016/S0140-6736(02)09335-2 Liu, P. B., Shah, P., Croadell, S., and Gilbertson, T. A. (2011). Transient receptor potential channel type M5 is essential for fat taste. J. Neurosci. 31, 8634–8642. doi: 10.1523/JNEUROSCI.6273-10.2011 Liu, R. H., Matsuura, M., and Matsuura, S. (2004). The expression and functional role of nicotinic acetylcholine receptors in rat adipocytes. J. Pharmacol. Exp. Ther. 310, 52–58. doi: 10.1124/jpet.103.065037 Lucero, M. T., and Pappone, P. A. (1989). Voltage-gated potassium channels in brown fat cells. J. Gen. Physiol. 93, 451–472. doi: 10.1085/ijgp.93.3.451 Ludy, M. J., Moore, G. E., and Mattes, R. D. (2011). The effects of capsaicin and capsaicin on energy balance: critical review and meta-analyses of studies in humans. Chem. Senses 37, 103–121. doi: 10.1093/chemse/bjr100 Ma, S., Yu, H., Zhao, Z., Luo, Z., Chen, J., Ni, Y., et al. (2012). Activation of the cold-sensing TRPM8 channel triggers UCP1-dependent thermogenesis and prevents obesity. J. Mol. Cell Biol. 4, 88–96. doi: 10.1039/jmbi/mj0101 MacFarlane, S. N., and Sonheimer, H. (2000). Changes in ion channel expression accompany cell cycle progression of spinal cord astrocytes. Glu 30, 39–48. doi: 10.1006/glci.1999.0127 Maenhaut, N., and Van de Voorde, J. (2011). Regulation of vascular tone by adipocytokines. Bmc Med. 9.25. doi: 10.1186/1710-1538-9-25 Marks, D. R., and Faddoul, D. A. (2007). Post-synaptic density 95 (PSD-95) affects insulin induced Kv1.3 channel modulation of the olfactory bulb. J. Neurochem. 103, 1608–1627. doi: 10.1111/j.1471-4197.2007.04870.x Marrero, M. B., Lucas, R., Salet, C., Hauser, T. A., Mazurov, A., Lippiello, P. M., et al. (2010). An α7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J. Pharmacol. Exp. Ther. 332, 173–180. doi: 10.1124/jpet.109.154633 Mancia, G. J. A. (2000). Body-weight regulation: causes of obesity. Proc. Natl. Acad. Sci. USA 97, 337–345. doi: 10.1073/pnas.97.02.0080106340000380 Mcardle, W. D., Katch, F. L., and Katch, V. L. (2008). Fisiologia do Exercicio: Energia, Nutricão e Desempenho Humano, 6 Edn. Rio de Janeiro: Guanabara Koogan.
Rowe, I. C., Boden, P. R., and Ashford, M. L. M. (1996). Potassium channel dysfunction in hypothalamic glucose-receptive neurons of obese Zucker rats. J. Physiol. 497, 365–377. doi: 10.1113/jphysiol.1996.sp021774
Russ, U., Ringer, T., and Siemen, D. (1993). A voltage-dependent and a voltage-independent potassium channel in brown adipocytes of the rat. Biochem. Biophys. Acta 1153, 249–256. doi: 10.1016/0005-2736(93)90412-S
Satapathy, S. K., Ochani, M., Dancho, M., Hudson, L. K., Rosas-Ballina, M., Valdes-Ferrer, S. I., et al. (2011). Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Mol. Med. 17, 599–606. doi: 10.2101/molmed.2011.00083
Scherer, P. E., Williams, K. W., Donato, J. Jr., Lee, C. E., Zhao, J. J., Elmquist, J. K. (2011a). Modulation of the POMC neurons. Circ. Res. 111, 191–200. doi: 10.1161/CIRCRESAHA.112.270751
Tallam, L. S., Stec, D. E., Willis, M. A., Silva, A. A., and Hall, J. E. (2005). Brown adipose tissue: mechanisms and potential therapeutic targets. Circ. Res. 111, 191–200. doi: 10.1161/CIRCRESAHA.112.270751
Tamura, Y., Iwasaki, Y., Narukawa, M., and Watanabe, T. (2012). Ingestion of cinnamonaldehyde, a TRPA1 agonist, reduces visceral fats in mice fed a high-fat and high-sucrose diet. J. Nutr. Sci. Vitaminol. 58, 9–13. doi: 10.3177/jnsv.58.9
Thaler, J. P., Guynet, S. J., Dorfman, M. D., Wisse, B. E., and Schwartz, M. W. (2013). Hypothalamic inflammation: marker or mechanism of obesity pathogenesis? Diabetes 62, 2629–2634. doi: 10.2337/db12-1605
Tong, Q., Ye, C., Jones, J. E., Elmqquist, J. K., and Lowell, B. B. (2008). Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance. Nat. Neurosci. 11, 998–1000. doi: 10.1038/nn.2167
Wu, Q., Boyle, M. P., and Palminter, R. D. (2009). Loss of GABAergic signaling by AgRP neurons to the parabrachial nucleus leads to starvation. Cell 137, 1225–1234. doi: 10.1016/j.cell.2009.04.022

Xu, J., Koni, P. A., Wang, P., Li, G., Kaczmarek, L. K., Wu, Y., et al. (2009). Loss of GABAergic signaling by AgRP neurons to the parabrachial nucleus leads to starvation. Cell 137, 1225–1234. doi: 10.1016/j.cell.2009.04.022

Xu, J., Wang, P., Li, Y., Li, G., Kaczmarek, L. K., Wu, Y., et al. (2004). The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc. Natl. Acad. Sci. U.S.A. 101, 3112–3117. doi: 10.1073/pnas.0308450100

Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., et al. (2001). The fat-derived hormone adiponectin reverses insulin resistance associated with both lipatrophy and obesity. Nat. Med. 7, 941–946. doi: 10.1038/90984

Yang, S. B., Tien, A. C., Boddupalli, G., Xu, A. W., Jan, Y. N., and Jan, L. Y. (2012). Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. Neuron 75, 425–436. doi: 10.1016/j.neuron.2012.03.043

Ye, L., Kleiner, S., Wu, I., Sah, R., Gupta, R. K., Banks, A. S., et al. (2012). TRPV4 is a regulator of adipose oxidative metabolism, inflammation, and energy homeostasis. Cell 151, 96–110. doi: 10.1016/j.cell.2012.08.034

Yoshida, T., Umekawa, T., Wakabayashi, Y., Sakane, N., and Kondo, M. (1994). Mechanism of anti-obesity action of benidipine hydrochloride in mice. Int. J. Obes. Relat. Metab. Disord. 18, 776–779.

Yoshioka, M., St-Pierre, S., Drapeau, V., Dionne, I., Doucet, E., Suzuki, M., et al. (1999). Effects of red pepper on appetite and energy intake. Br. J. Nutr. 82, 115–123. doi: 10.1079/5007114599001269

Zahorska-Markiewicz, B., Jonderko, K., Lelek, A., and Skrzypek, D. (1986). Gastric emptying in obesity. Hum. Nutr. Clin. Nutr. 40, 309–313.

Zaragoza, R. M., Lopez, M. L., Villanueva, S. L., Ortiz, R. A., and Villanueva, G. L. (2005). Efficacy and safety of slow-release fenproporex for the treatment of obesity. Rev. Mex. Cardiol. 16, 146–154.

Zawar, C., Plant, T. D., Schirra, C., Konnerth, A., and Neumcke, B. (1999). Cell-type specific expression of ATP-sensitive potassium channels in the rat hippocampus. J. Physiol. 514, 327–341. doi: 10.1111/j.1469-7793.1999.315ax.x

Zemel, M. B., Kim, J. H., Woychik, H. P., Michaud, E. J., Kadwell, S. H., Patel, I. R., et al. (1995). Agouti regulation of intracellular calcium: role in the insulin resistance of viable yellow mice. Proc. Natl. Acad. Sci. U.S.A. 92, 4733–4737. doi: 10.1073/pnas.92.11.4733

Zhang, L. L., Liu, D. Y., Ma, L. Q., Luo, Z. D., Cao, T. B., Zhong, J., et al. (2007). Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ. Res. 100, 1063–1070. doi: 10.1161/01.RES.0000262633.84580.8b

Zhang, Y., Hoon, M. A., Chandrashekar, J., Mueller, K. L., Cook, B., Wu, D., et al. (2003). Coding of sweet, bitter, and umami tastes: different receptor cells sharing similar signaling pathways. Cell 112, 293–301. doi: 10.1016/S0092-8674(03)00071-0

Zhang, Z., Zhang, W., Jung, D. Y., Ko, H. J., Lee, Y., Friedline, R. H., et al. (2012). TRPM2 Ca2+ channel regulates energy balance and glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 302, E807–E816. doi: 10.1152/apend.00239.2011

Zhu, A. Z. X., Renner, C. C., Hatsuakami, D. K., Benowitz, N. L., and Tyndale, R. F. (2013). CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. Addiction 108, 1818–1828. doi: 10.1111/add.12250

Zhu, Y., Yang, J., Yeh, F., Cole, S. A., Haack, K., Lee, E. T., et al. (2014). Joint association of nicotinic acetylcholine receptor variants with abdominal obesity in American Indians: the Strong Heart Family Study. PLoS ONE 9:e102220. doi: 10.1371/journal.pone.0102220

Zoli, M., and Picciotto, M. R. (2012). Nicotinic regulation of energy homeostasis. Nicotine Tob. Res. 14, 1270–1290. doi: 10.1093/ntr/nts159

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Vasconcelos, Souza, Pinheiro and Silva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.